Novartis halts early trial of new cancer drug for business reasons
NCT ID NCT04895748
Summary
This was an early safety study for a new drug called DFF332, designed to block a protein that helps certain cancers grow. It was tested alone and in combinations with other cancer drugs in adults with advanced kidney cancer and other tumors driven by specific genetic changes. The sponsor stopped the trial early for business reasons, not safety, before testing the planned combinations or enrolling most patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical
Duarte, California, 91010, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloane Ketterin Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Brno, 656 53, Czechia
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Koto Ku, Tokyo, 1358550, Japan
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
WA Uni School Of Med
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.